Dihexa

Multiple WSU studies used the scopolamine model of amnesia — blocking muscarinic acetylcholine receptors to produce anterograde memory impairment — and tested Dihexa's ability to reverse the deficit in Morris Water Maze performance. Dihexa reversed scopolamine-induced spatial learning deficits dose-dependently, and did so at concentrations substantially lower than comparator compounds. This is the most consistently replicated behavioral finding in the Dihexa literature from WSU. The scopolamine model is a validated and widely used pharmacological amnesia model. The behavioral endpoints (time to find hidden platform, search strategy analysis) are objective and less susceptible to manipulation than molecular assays. Grade C: WSU primary; behavioral data not directly implicated in misconduct; still single-lab.

Wright and Harding lab studies documented that Dihexa improved spatial learning in aged rats — animals whose cognitive performance had declined with normal aging rather than pharmacological insult. This is a more naturalistic model and more relevant to the anti-aging cognitive enhancement application the community is primarily interested in. The improvement in aged rats performing Morris Water Maze and Barnes Maze tasks was the key finding that positioned Dihexa as a nootropic rather than merely an amnesia treatment. Same provenance caveats apply. Grade C.

Sun et al. (Brain Sciences, 2021) — from a Chinese academic group with no WSU affiliation — studied Dihexa in APP/PS1 transgenic mice, a standard Alzheimer's disease animal model. Findings: Dihexa improved spatial memory (Morris Water Maze and novel object recognition), activated PI3K/AKT signaling in hippocampal tissue, and reduced amyloid-associated pathology markers. This is the most important independent replication in the Dihexa evidence base — it comes from a different country, different institution, different research group, and was published after the research integrity concerns emerged. Its independence from the WSU program means it carries meaningful weight despite being a single study. Grade C: one independent group; animal model; not human data; published in a mid-tier journal.

A 2025 biorXiv preprint (peer review status at time of writing: not yet peer-reviewed) from a WSU-adjacent but independently operating research group documented Dihexa improving working memory deficits in a rat model of repeated mild TBI. The HGF/MET dimerization antagonist Hinge blocked these effects, providing mechanistic support for the HGF/c-Met pathway. This is a preprint and requires peer review for full weighting. It represents a meaningful independent contribution to the behavioral literature that does not rely on the implicated research. Grade C: preprint status; independent from implicated group; animal TBI model.

The community's most common use — cognitive enhancement in neurologically healthy adults — has zero clinical trial evidence. The extrapolation from 'reverses amnesia in scopolamine-treated rats' to 'enhances cognition in healthy humans' follows the same leap that has been made with many nootropics and failed in controlled human trials. The biological argument is coherent: if HGF/c-Met signaling supports synaptic plasticity, potentiating it pharmacologically could enhance learning and memory in healthy individuals as well as pathological states. The clinical evidence for this does not exist for Dihexa, and the failure of the clinical prodrug in diseased patients (where the signal should be easiest to detect) is not encouraging for the healthy adult application. Grade X.

Dihexa: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide. A modified hexapeptide — the name 'Dihexa' reflects 'di-hexanoic' components. Molecular weight approximately 492 Da. The compound is small by peptide standards — this is critical for its oral bioavailability and BBB penetration. Key structural modifications from the angiotensin IV parent: N-terminal hexanoic acid cap (increases lipophilicity, resists aminopeptidase N-terminal cleavage); C-terminal aminohexanoic acid amide (extends stability against C-terminal degradation); overall increased lipophilicity profile enabling passive membrane diffusion across the blood-brain barrier.

Most peptides in this book are injectable specifically because peptides are degraded in the GI tract. Dihexa is an exception: its small size (~492 Da), increased lipophilicity from the hexanoic modifications, and structural resistance to typical peptidase degradation allow a meaningful fraction to survive GI transit and reach systemic circulation. WSU pharmacokinetic studies reported detectable brain levels after oral administration. This is pharmacologically unusual and practically significant — it means oral capsules or solutions are a viable administration route, not merely a community workaround. The oral bioavailability is lower than IV or SubQ would be, but it is pharmacologically non-trivial. Importantly, these pharmacokinetic studies come from the WSU lab, and share the general provenance concerns of that research program.

Dihexa's ability to cross the blood-brain barrier after systemic administration has been demonstrated in WSU animal studies — detectable brain concentrations after oral and peripheral administration. The mechanism is consistent with passive diffusion for a small, lipophilic molecule. The parent compound angiotensin IV is known to affect CNS function after peripheral administration, providing precedent for CNS penetration of this class. BBB penetration is one of the most supported pharmacokinetic properties of Dihexa — both from the structural rationale and from the preclinical measurements — and is the property least likely to be directly affected by the data integrity concerns (which centered on protein expression western blots, not pharmacokinetic measurements).

Dihexa was designed for extended plasma half-life through resistance to both aminopeptidase (N-terminal hexanoyl cap) and carboxypeptidase (C-terminal amide modification) degradation. The WSU group reported a long circulating half-life — specific values from published WSU studies should be interpreted in the context of the overall provenance concerns, but the structural chemistry supporting extended stability is sound independent of the disputed western blot data. Community users report effects persisting 12-24 hours after a single oral dose, consistent with a compound with slow systemic clearance.

Community Dihexa: available as oral powder (encapsulated or loose), oral solution, and sometimes as nasal spray or transdermal cream (community-developed routes with no pharmacokinetic validation). Lyophilized powder: store at -20C; reconstitute for solution dosing. Capsules: room temperature storage acceptable for most preparations. Mass spectrometry confirming ~492 Da is the identity check. HPLC purity 98%+. Pricing 2026: research vendor, 100 mg oral powder: $50-120 depending on vendor.

The hepatocyte growth factor (HGF) / c-Met signaling pathway is extensively characterized across decades of independent research — the vast majority of which has nothing to do with Dihexa. HGF is a multifunctional cytokine originally identified as a hepatocyte mitogen but now known to have broad roles in organ development, tissue repair, and neurotrophism. c-Met is the receptor tyrosine kinase for HGF, expressed on neurons, astrocytes, and oligodendrocytes throughout the brain. HGF/c-Met signaling in the CNS: promotes neuronal survival (anti-apoptotic via PI3K/Akt); stimulates dendritic arborization (via Rac1/Cdc42 cytoskeletal signaling); enhances synaptic density and LTP (via ERK/MAPK pathway); and supports neurogenesis in the hippocampus. HGF/c-Met signaling is reduced in hippocampal tissue from Alzheimer's disease patients — this has been confirmed in post-mortem human brain studies from multiple independent laboratories. None of this requires Dihexa for its establishment — it is the independent scientific foundation into which Dihexa was designed to intervene. Grade A for the HGF/c-Met pathway biology.

Dihexa's proposed mechanism: allosteric potentiation of HGF at c-Met. Specifically, Dihexa is proposed to facilitate HGF dimerization — bringing two HGF molecules together in the conformation required for high-affinity c-Met binding — rather than acting as a direct c-Met agonist. This is mechanistically distinct: Dihexa amplifies the activity of endogenous HGF; it does not substitute for it. The Benoist et al. (2014) [2] paper from WSU identified c-Met as the molecular target by showing that an HGF antagonist (Hinge) blocked Dihexa's cognitive effects in Morris Water Maze. This remains one of the most important mechanistic papers — and it is from the WSU research group. The question the data integrity issue raises: which specific western blot experiments in the mechanistic lineage are affected? The published misconduct findings focused on Kawas's doctoral dissertation. The Benoist 2014 paper postdates her doctoral work and involves different authors. The exact boundaries of compromised vs uncompromised data in this research program are not fully publicly established. Grade C: the mechanism is plausible and partially supported by Benoist 2014 and independent HGF/c-Met biology; the specific data integrity scope affecting Dihexa mechanistic studies is not fully public.

THE DATA INTEGRITY ISSUE — WHAT IS AND ISN'T KNOWN

What is confirmed: Leen Kawas's doctoral dissertation (WSU, Harding lab) contained western blot images that appeared manipulated. WSU investigated and found issues. Kawas resigned as Athira CEO. Athira settled $4M with DOJ for False Claims Act related to NIH grants referencing the research. What is NOT confirmed: the specific papers and datasets from the Dihexa/HGF research program that are directly compromised. The misconduct investigation focused on Kawas's doctoral work — not the entire WSU Dihexa program. The behavioral data (Morris Water Maze performance in rodents) has not been specifically identified as falsified. The 2021 independent replication (Sun et al.) was not from WSU and is not affected. The 2025 biorXiv preprint (independent WSU-adjacent lab) is not directly from the implicated research group. The honest position: some of the foundational mechanistic support for Dihexa's HGF/c-Met mechanism came from research that has been compromised. The extent of the compromise as it specifically applies to Dihexa evidence is not fully delineated. This uncertainty should propagate directly to evidence grading.

The synaptogenesis claim — that Dihexa stimulates physical formation of new synaptic connections, including dendritic spine growth, through c-Met/Rac1/Cdc42 cytoskeletal signaling — is the primary basis for the community's excitement about the compound. The mechanism is: c-Met activation → β-arrestin and Rac1/Cdc42 signaling → actin cytoskeleton remodeling → dendritic spine emergence and synaptic contact formation. WSU studies used patch clamp electrophysiology and confocal microscopy to document increased synapse density in hippocampal neurons treated with Dihexa in vitro. The distinction from neurotransmitter-modulating nootropics is real: if Dihexa stimulates structural synaptogenesis, the effects could be more durable than compounds that simply enhance neurotransmitter availability. This distinction drives the community's interest. Whether the specific synaptogenesis data from WSU is among the compromised findings is not publicly established. Grade C-D pending clarity on which specific datasets are affected.

c-Met activation via PI3K/Akt signaling is anti-apoptotic in neurons — well-established in the independent HGF/c-Met literature. If Dihexa potentiates c-Met, it should produce neuroprotective anti-apoptotic effects through this pathway. Sun et al. (2021) documented that Dihexa in APP/PS1 Alzheimer's model mice activated PI3K/AKT signaling and improved memory — providing independent support for this aspect of the mechanism from a non-WSU group. Grade C: independent replication of PI3K/AKT involvement; animal model; not human data.

Year

Event

1990s-2000s

WSU researchers Wright and Harding develop angiotensin IV analog program; HGF/c-Met identified as mechanism

2013

McCoy et al. — foundational Dihexa behavioral paper in rats; Harding lab WSU

2014

Benoist et al. — HGF/c-Met identified as Dihexa's molecular target using Hinge antagonist; WSU

2014-2015

M3 Biotechnology founded as WSU spin-off; Leen Kawas (former Harding lab PhD student) becomes CEO

2019

M3 Biotechnology rebrands as Athira Pharma; raises significant capital; LIFT-AD trial initiated for fosgonimeton

2021 (early)

PubPeer and independent researchers flag concerning western blot images in publications associated with the WSU Harding lab HGF/c-Met research

2021 (mid)

Athira Pharma announces internal investigation; WSU begins review

October 2021

Leen Kawas resigns as Athira CEO; Athira stock drops ~67% across 2021

2021-2022

WSU investigation proceeds; multiple papers under review; Kawas's doctoral dissertation identified as containing manipulated images

December 2023

LIFT-AD trial reports: fosgonimeton fails to meet primary and secondary endpoints in Alzheimer's patients

January 2025

Athira Pharma agrees to pay $4 million to settle False Claims Act allegations related to NIH grants referencing compromised research

2025

biorXiv preprint from independent WSU-adjacent lab shows Dihexa improves TBI working memory in rats; provides some additional behavioral evidence not from implicated group

The research integrity events do not establish that Dihexa does not work. They establish that some of the foundational mechanistic evidence for how it works came from research that has been formally compromised. The behavioral data — rodents performing better in memory tasks after Dihexa administration — is the portion of the evidence base least likely to be directly falsified, because behavioral outcomes are harder to manipulate than western blot images (they require live animals, multiple observers, and standardized protocols). The mechanistic story — which specific proteins, at which concentrations, through which signaling cascades — is more vulnerable to the type of manipulation identified. The community's use of Dihexa rests more on behavioral outcomes than on western blot data, which is some reassurance. The clinical failure of fosgonimeton is more broadly discouraging — it suggests that HGF/c-Met modulation at this level of potentiation does not produce the hoped-for human cognitive benefits, even with a purpose-designed prodrug achieving higher brain exposure.

Fosgonimeton (ATH-1017) is not Dihexa — it is a phosphate prodrug of the Dihexa metabolite designed to achieve higher and more sustained brain levels. The LIFT-AD failure does not directly prove that Dihexa is inactive in humans. But it is the closest thing we have to human clinical data on this mechanistic pathway, and it was negative on both primary and secondary endpoints. The failure of a clinical-grade compound specifically designed to optimize HGF/c-Met potentiation in Alzheimer's patients — with a company's entire existence staked on the outcome — is meaningful information about whether HGF/c-Met modulation through this mechanism produces measurable human cognitive benefit. The community should weigh this.

Oral is Dihexa's most community-validated route and the pharmacologically most coherent one given its oral bioavailability and BBB penetration. Standard forms: powder in capsules (most common), oral solution (powder dissolved in water or MCT oil). Community consensus dose: 10-30 mg/day. Some users report starting at 1-5 mg/day to assess response. No dose-response study in humans exists. The doses used in WSU animal studies (typically in the nanomolar to micromolar range in vitro; rat behavioral studies used systemic doses of approximately 0.1-1 mg/kg) do not translate straightforwardly to human oral doses.

Some community users apply Dihexa topically — dissolved in DMSO or a penetrating cream base — to the scalp or forearm, hypothesizing improved CNS delivery. This route has no pharmacokinetic validation for Dihexa specifically. Skin penetration of small peptides is variable and highly preparation-dependent. DMSO as a carrier penetrates skin effectively but produces a characteristic breath odor (garlic-like) that many users find unacceptable. The transdermal route is a community innovation without evidence support.

Sublingual administration — holding a dissolved dose under the tongue for absorption through the sublingual mucosa — bypasses some GI degradation and achieves faster onset. Salivary peptidase activity still poses some degradation risk for sublingual peptide administration. Community use at 5-15 mg sublingually reported. No validated pharmacokinetic data.

Protocol

Dose

Route

Cycle

Notes

Conservative

5-10 mg

Oral, once daily morning

4 weeks on, 4-8 weeks off

Starting point; assess response; document baseline cognition

Standard community

15-30 mg

Oral, once daily morning

4-8 weeks on, 4-8 weeks off

Most commonly reported; no validated basis

Advanced

30 mg+

Oral or sublingual

4-6 weeks maximum

Higher doses; reports of activation effects that require breaks

Morning dosing is community consensus — consistent with a compound that may produce activating/stimulating cognitive effects that could interfere with sleep if taken later in the day. Some users report effects persisting 12-24+ hours, supporting once-daily dosing and morning timing. No circadian pharmacology study exists.

Community convention: cycle Dihexa rather than use continuously. The biological logic offered: sustained HGF/c-Met potentiation could theoretically downregulate endogenous HGF/c-Met signaling through receptor adaptation. Whether receptor downregulation actually occurs with chronic Dihexa use is not established. The cycles also limit cumulative exposure to a compound whose long-term safety is completely uncharacterized.

No published safety study exists for Dihexa in humans. No animal toxicology study has been published for Dihexa specifically. LIFT-AD (fosgonimeton, the prodrug) reported that 4 of 10 participants in the higher dose arm dropped out due to adverse events, and injection site reactions were the most common adverse effect. These are for the prodrug by injection, not oral Dihexa. The community's primary safety signal is self-reports from what is a very small population of users. The absence of reported disasters is not a safety database.

HGF/c-MET AND CANCER — THE MOST IMPORTANT SAFETY CONSIDERATION

The HGF/c-Met signaling pathway is not just a neuroprotective pathway — it is a major oncological driver. c-Met is overexpressed and activating-mutated in multiple cancers including lung, kidney, gastric, and hepatocellular carcinoma. HGF/c-Met signaling promotes tumor cell survival (anti-apoptotic via PI3K/Akt), tumor growth (proliferative via ERK/MAPK), invasion (cytoskeletal via Rac1), and angiogenesis (VEGF upregulation). c-Met inhibitors (cabozantinib, crizotinib, savolitinib) are approved anti-cancer drugs that work by blocking exactly the pathway that Dihexa activates. A compound that potentiates c-Met signaling system-wide is, by mechanism, operating in the same biological space as these oncology drugs — but in the opposite direction. This creates a theoretical cancer risk that is not hypothetical hand-waving but mechanistic biology. No carcinogenicity study of Dihexa has been published. The community's cancer risk from Dihexa is unknown and uncharacterized. For anyone with active malignancy, strong family cancer history, or known oncogenic mutations: this cancer concern is not dismissible. Discuss with an oncologist before any use.

• Overstimulation and agitation: the most commonly reported adverse effect in community users at higher doses. Cognitive activation that becomes uncomfortable — racing thoughts, inability to relax, irritability.
• Insomnia: related to the activating effects; managed by morning dosing and avoiding doses above individual tolerance threshold.
• Headache: occasionally reported, particularly at initiation or higher doses.
• GI discomfort: mild, occasionally reported with oral administration.
• 'Brain fog' in some users: paradoxically, some community users report cognitive fogginess or fatigue during use, particularly after the initial stimulation phase. Mechanism unclear.

• Active malignancy or strong cancer family history: c-Met agonism theoretical cancer concern — absolute contraindication in active cancer; discuss with oncologist before use with significant family history.
• Pregnancy: no safety data; avoid.
• Children and adolescents: neurodevelopmental concerns with pharmacological synaptogenesis during active CNS development; avoid.

Not FDA-approved. Research chemical. Not a controlled substance. Not WADA-listed. The patent landscape around fosgonimeton and related Dihexa analogs is held by Athira Pharma (formerly M3 Biotechnology). Community Dihexa is synthesized independently of Athira's patent portfolio.

Semax upregulates endogenous BDNF through ACTH/MC4R signaling. Dihexa potentiates c-Met through HGF allosteric modulation. These are mechanistically distinct pathways that both ultimately support synaptic plasticity and neuroplasticity — one through BDNF/TrkB, the other through HGF/c-Met. Non-redundant. Both oral (Semax intranasal for community; Dihexa oral). The Russian nootropic + HGF axis combination. No interaction data. Theoretical additive neuroplasticity support from two independent growth factor systems.

Cerebrolysin contains NGF-like and BDNF-like fragments; also proposed to contain HGF-like activity. If true, combining with Dihexa (HGF potentiator) could be partially redundant at the HGF/c-Met level. This combination is sometimes used in post-TBI recovery protocols. The mechanistic overlap at HGF/c-Met is a consideration worth noting, though the partial redundancy is unlikely to produce harm — just diminishing returns from the combined HGF component.

Some advanced biohackers combine Dihexa (synaptogenesis/neuroplasticity) with FOXO4-DRI (senescent cell clearance). The logic: clear the aged, dysfunctional cells first; then use Dihexa to support structural neuroplasticity during the recovery phase. The sequence is the same as with other restoration-after-clearance combinations. No interaction data. Biologically coherent sequencing.

c-Met inhibitors are used as cancer treatments (cabozantinib, crizotinib). Dihexa activates c-Met; c-Met inhibitors block it. These are pharmacologically opposing compounds. Anyone receiving cancer treatment involving c-Met inhibitors must not use Dihexa — the pharmacological conflict is direct and mechanism-level.

Timeframe

Community-Reported

Hours 2-6 (first dose)

Some users report acute activation effects — heightened mental clarity, increased motivation, faster associative thinking. Others report nothing. Variable first-dose response is common.

Days 3-7

Emergence of the most commonly reported benefits: improved working memory, faster information retrieval, enhanced verbal fluency. Some users report this builds over the first week.

Week 2-4

Peak cognitive effects reported. Improved memory consolidation, better ability to retain and recall new information. The structural synaptogenesis hypothesis predicts durable improvements rather than tolerance — some users report continued improvement through the cycle.

Post-cycle

Community consensus: effects persist 2-6 weeks after cycle ends. This is the most discussed feature of Dihexa vs conventional nootropics — the persistence of benefit after stopping. Consistent with structural synaptogenesis hypothesis if true. Not validated.

Dihexa has accumulated an unusual community mythology — the '10 million times more potent than BDNF' claim, the 'build new synapses' framing, the Athira story. Users approaching Dihexa with high expectations in a context where the compound has no blinded human trial data are particularly vulnerable to expectation/placebo effects. The community's subjective positive reports must be weighted against the strong expectation bias created by the compound's reputation. This does not mean the effects aren't real — it means subjective reports are not reliable evidence in this context.

• Treating the '10 million times more potent than BDNF' figure as validated: this claim came from in vitro WSU assays, shares provenance concerns of that research program, and represents a cell culture potency comparison not a clinical efficacy comparison. Treat with explicit skepticism.
• Ignoring the data integrity context: using Dihexa without understanding that its foundational mechanistic evidence comes from a research program that produced formally acknowledged research misconduct is using a compound without the most important evaluative context.
• Treating fosgonimeton's LIFT-AD failure as irrelevant to Dihexa: fosgonimeton is the optimized clinical prodrug of Dihexa's mechanism. Its failure in Phase 2/3 Alzheimer's trials is the closest human clinical data available about whether this mechanism produces cognitive benefit. It failed.
• Ignoring the c-Met cancer concern: c-Met is a proto-oncogene. Potentiating c-Met system-wide with no cancer risk characterization is a theoretical concern that should not be dismissed because it hasn't been specifically documented in community users.
• Long-term continuous use: no long-term safety data. No chronic toxicology study. Cycling is warranted for an uncharacterized compound operating in the oncology-adjacent HGF/c-Met pathway.

McCoy AT, et al. (2013) [1]. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. [McCoy / Harding lab WSU; Dihexa foundational behavioral paper; scopolamine reversal and aged rat spatial learning; WSU primary; behavioral data not directly implicated in misconduct but shares overall provenance context]

Benoist CC, et al. (2014). Identification of novel small molecule HGF/MET signaling inhibitors. Biochemistry. [Benoist / Harding lab WSU; HGF antagonist (Hinge) blocks Dihexa effects — identifies c-Met as the molecular target; this postdates Kawas's doctoral work and involves different primary authors; mechanistic anchor paper]

Sun XJ, et al. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sciences. 11(11):1487. doi:10.3390/brainsci11111487. [INDEPENDENT — Chinese academic group; no WSU affiliation; APP/PS1 Alzheimer's model mice; spatial memory improvement; PI3K/AKT activation; the most important independent paper in the Dihexa literature]

McCoy AT, et al. (2025) [4]. Hepatocyte Growth Factor/MET Activator Rescues Working Memory Following Traumatic Brain Injury. biorXiv (preprint). 2025.09.25.678537. [Independent WSU-adjacent lab; TBI working memory improvement; HGF/MET dimerization antagonist blocks effect; PREPRINT — not yet peer reviewed; meaningful independent behavioral contribution]

Hepatocyte growth factor (HGF) as a neurotrophic factor [multiple independent reviews]. HGF/c-Met signaling in neuronal survival, dendritic arborization, synaptogenesis — the independent neuroscience literature that constitutes the most solid part of Dihexa's mechanistic foundation. Authors: Maina F et al., Bhatt DL et al., Finsterwald C et al. [not Dihexa-specific; the background biological validity independent of WSU controversy]

Athira Pharma LIFT-AD trial. (December 2023). Fosgonimeton (ATH-1017) fails primary and secondary endpoints in Phase 2/3 LIFT-AD Alzheimer's trial. [Phase 2/3 trial of the Dihexa prodrug; primary and secondary endpoints not met; higher dose arm had 40% dropout rate from adverse events; clinically most relevant evidence for HGF/c-Met potentiation in human cognition — negative result]

U.S. Department of Justice. (January 2025). Athira Pharma settles False Claims Act allegations for $4.1 million. Related to NIH grant applications referencing research with manipulated images from Leen Kawas's doctoral dissertation (Washington State University, Harding lab). [The formal legal resolution of the research integrity events; establishes that federally acknowledged research fraud occurred in the scientific lineage of this compound]

ALZFORUM Therapeutics: Fosgonimeton. https://www.alzforum.org/therapeutics/fosgonimeton. [Independent tracking of the Athira/fosgonimeton clinical program including the data integrity events, LIFT-AD trial timeline, and results]

Feature

Dihexa

Semax

BPC-157

Cerebrolysin

Human RCT data

Zero (fosgonimeton failed)

Russian clinical approval

Zero

Dozens (mostly industry-sponsored)

Animal evidence quality

C — behavioral (not directly implicated); C-D mechanistic (compromised provenance)

B — Dolotov 2006 independent replication

B — single lab, extensive animal data

B — independent + industry sponsored

Data integrity concern

YES — formal misconduct finding; CEO resigned; $4M settlement

None identified

Minor — single-lab concentration, no formal misconduct

EVER Neuro Pharma commercial concentration (financial, not data fraud)

Clinical translation

Fosgonimeton LIFT-AD: FAILED Phase 2/3

Russian pharmaceutical approval for stroke/cognitive indications

No clinical program

CASTA: independent RCT failed primary endpoint

Cancer safety concern

HIGH — c-Met proto-oncogene potentiation; uncharacterized

None identified

None identified

None identified

Community use justification

Behavioral preclinical + limited independent replication + HGF biology

Russian clinical + Dolotov independent replication

Extensive preclinical only

Decades of use + approved in 40+ countries

• '10 million times more potent than BDNF' is a real clinical fact: this is an in vitro potency comparison in a specific cell culture assay from a lab whose research has been compromised. It is not a validated clinical efficacy comparison. It should not be cited as a fact.
• The data integrity issue only affects the mechanism, not whether Dihexa works: the mechanism and the behavioral effects are not fully separable. If the mechanistic story is partially fabricated, the interpretation of the behavioral findings changes. The behavioral data may be valid; treating it as fully independent of the mechanistic controversy overstates the separation.
• Fosgonimeton's failure is irrelevant because it's a different compound: fosgonimeton was specifically designed to be the optimized clinical version of Dihexa's mechanism — higher brain exposure, better pharmacokinetics, same HGF/c-Met potentiation. Its failure in Alzheimer's patients is highly relevant clinical information about whether this mechanism benefits human cognition.
• The c-Met cancer concern is theoretical so it doesn't matter: c-Met is a proto-oncogene with multiple approved cancer drugs that work by blocking it. Potentiating it systematically with no carcinogenicity study is not a theoretical concern to be dismissed — it is an uncharacterized real concern that no one has tested.

— End of Dihexa —

THE PEPTIDE BIBLE | Dihexa | For Research & Educational Purposes Only